Company profile
Willingsford Limited
Passive Immunotherapy treatment for wounds and wounds associated with dermatological conditions - Willingsford Healthcare
New disruptive technology for treating wound infections. Approved for all wound types. Version for wounds and pressure ulcers in spinal cord injury (SCI)
Company events
Reference milestones and recent Companies House filing stream events.
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts due
Accounts DueNext accounts due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Integrated use of telemedicine and AI in wound treatment - contributing to public sector financial and environmental sustainability and resilience during pandemics.
1 Oct 2020 to 31 Dec 2020
Cost of healthcare in the UK and world-wide continues to place an increasing burden on public finances, e.g. the 2019 NHS budget was £134 billion. There are annually 2.3 million wounds in the UK, but treatment times are long and 39% remain unhealed because existing treatments are ineffective. Wounds therefore annually cost the NHS £17.3 bn and require 278...
RCT protocol development to evaluate MPPT in venous leg ulcers
1 May 2019 to 30 Apr 2020
"The main reason wounds and ulcers have difficulty or fail to heal is infection. For the past decade, it has been standard medical practice to use antimicrobials to treat wound infections, but several clinical studies have shown that they have minimal effects and NICE and the FDA no longer encourage their use. Furthermore, both antibiotics and antiseptics...
Novel drying method for advanced materials
1 May 2017 to 30 Apr 2018
Acapsil is a CE-marked novel first-in-class advanced biomaterial, which has demonstrated effects in wound care. Annually in the UK, 2.2 mill wounds require treatment causing direct costs to the NHS of £5.3 bn. Acapsil accelerates wound healing by 60% and reduces bed-days by 31% for hospital in-patients with acute and chronic wounds and ulcers. Estimates i...
SertaSil - novel medical device for advanced wound care
1 Jan 2012 to 30 Sep 2015
The NHS spends each year over £3bn on wound care and at any one time in the UK there are over 600,000 wounds that cannot heal. In the EU there are over 12 mil wounds and burns annually requiring extended treatment or hospitalisation. However, current treatments have limited effects and there is an urgent need for improved wound care products. SertaSil is ...